<DOC>
	<DOCNO>NCT00518115</DOCNO>
	<brief_summary>This study placebo-controlled study patient Type 2 Diabetes Mellitus either take diabetes medication take metformin . This study investigate safety , tolerability , efficacy Albiglutide ( GSK716155 ) measure level Albiglutide ( GSK716155 ) bloodstream give 16 week . As comparison , subject receive exenatide instead Albiglutide ( GSK716155 ) . The study involve weekly visit 17 week , less frequent follow-up visit additional 10 week . Assessments include repeat blood sample monitoring side effect .</brief_summary>
	<brief_title>Out-Patient Study Patients With Type 2 Diabetes Mellitus Who Are Taking Diabetes Medication Metformin Only</brief_title>
	<detailed_description>A 16-week , parallel-group , double-blind , randomize , placebo-controlled , multicenter , dose-ranging study evaluate efficacy , safety tolerability multiple dose multiple treatment regimen Albiglutide ( GSK716155 ) Byetta open-label active reference , subject Type 2 Diabetes Mellitus .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>rGLP-1 protein</mesh_term>
	<criteria>Has type 2 diabetes mellitus define criterion American Diabetes Association recognize World Health Organization Expert Committee Diagnosis Classification Diabetes Mellitus [ American Diabetes Association , 2004a ] least three month precede screening Has concurrent type 2 diabetes mellitus therapy : Must diet exercise treat ; must take antidiabetic medication least three month prior prescreening Monotherapy metformin , history stable dose least three month prescreening ( take one oral antidiabetic agent ) Has HbA1c level screen ≥7 ≤10 % Is male female 18 75 year age , inclusive , screen Has body mass index ≥20 ≤40 kg/m² If subject smoker , must able abstain clinic visit If female , eligible enter participate throughout study , include followup period : 1 ) If nonchildbearing potential ( i.e . physiologically incapable become pregnant { tubal ligation } , include female postmenopausal [ &gt; 1 year without menstrual period ] ) ; , 2 ) If childbearing potential , negative pregnancy test screen ( serum ) baseline ( urine ) : 3 ) Has male partner sterile prior female subject 's entry study sole sexual partner female subject , 4 ) Uses doublebarrier method contraception ; condom ( spermicide ) intrauterine device acceptable , 5 ) Uses hormonal contraceptive ( oral , depot , patch , etc ) doublebarrier method contraception outline , , 6 ) Abstains sexual intercourse , 7 ) Is samesex partner participate bisexual activity risk pregnancy Signs date informed consent studyrelated procedure perform Has metabolic disease include limited : 1 ) Diagnosis type 1 diabetes mellitus , 2 ) Uncorrected thyroid dysfunction ( NOTE : subject hypothyroidism stable dose thyroid replacement therapy least three month prior screen , screen thyroidstimulating hormone within limit normal may participate ) Has qualitative change lifestyle , opinion investigator , would affect subject 's weight disease status Had previous use insulin within one month prior screen , seven total day insulin treatment within three month prior screen Has clinically significant cardiovascular and/or cerebrovascular disease include , limited : 1 ) Previous history stroke transient ischemic attack , 2 ) Active , unstable coronary heart disease within past six month , 3 ) Documented myocardial infarction within year prior screen 4 ) Any cardiac surgery include percutaneous transluminal coronary angioplasty coronary artery bypass graft surgery within year prior screen 5 ) Unstable angina 6 ) Clinically significant arrhythmia valvular heart disease within past year 7 ) Congestive heart failure New York Heart Association Class II Class IV symptom . Class I acceptable . 8 ) Untreated hypertension , systolic pressure great 160mm Hg and/or diastolic pressure great 95mm Hg . 9 ) ECG exclusion criterion : Heart rate &lt; 40 &gt; 110 beat per minute , PR Interval &lt; 120 &gt; 210msec , QRS duration &lt; 70 &gt; 120msec , QTc interval ( Bazett ) &gt; 450msec &gt; 480msec bundle branch block Has fasting serum triglyceride ≥800mg/dL 9mmol/L screening ( Visit 2 ) . Subjects receive lipidlowering therapy must dose therapy past three month . Fasting defined food/drink least eight hour prior sample If female , currently lactate , pregnant , actively try become pregnant Has significant renal disease manifest one following : 1 ) Creatinine clearance &lt; 60mL/min . ( estimate serum creatinine demographic data use modification diet renal disease calculation ; refer SPM/ISFM ) , 2 ) Urine albumin excretion ≥500 µg/mL urine spot check , 3 ) Known loss kidney either surgical ablation , injury , disease Has history significant comorbid disease active within last six month ( e.g. , gastrointestinal disease ) Has history pancreatitis within five year prior randomization Has document history chronic advance hepatobiliary disease include history , positive laboratory result , hepatitis screening ( Visit 2 ) , and/or clinically significant hepatic enzyme elevation include : 1 ) Any two follow enzyme great 1.5 time upper limit normal ( ULN ) value : alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , alkaline phosphatase ( ALP ) , 2 ) Any one enzymes two time great ULN value AND total direct bilirubin &gt; 1.5 time ULN Has history alcohol substance abuse within past year , determine investigator positive urine drug screen screen ( Visit 2 ) treatment : 1 ) Unwilling refrain use excessive alcohol illicit drug adhere protocolstated restriction participate study , 2 ) History alcohol abuse define average weekly intake great 21 unit average daily intake great three unit ( male ) define average weekly intake great 14 unit average daily intake great two unit ( female ) . One unit equivalent halfpint beer one measure spirit one glass wine , 2 ) The investigator exercise medical judgment determine urine drug screen indicate Is currently take prohibit concomitant medication list Section 6.6.2 Has clinically significant anemia ( i.e. , hemoglobin &lt; 12.0g/dL &lt; 120.0g/L male &lt; 11.0g/dL &lt; 110.0g/L female ) abnormal hematological profile consider investigator clinically significant Has know allergy formulation excipients , history drug allergy , , opinion responsible study physician , contradict participation Received treatment investigational drug participate clinical trial previous 30 day Has prior use investigational agent long halflives great seven day within three month prior screen Has prior use GLP1 analog , include GSK716155 In opinion investigator , risk noncompliance study procedure , read , understand , complete studyrelated material , particularly inform consent Has concurrent condition clinically significant abnormality identify screen physical examination , laboratory test , ECG , include pulmonary , neurological , inflammatory disease , , opinion investigator , may affect interpretation efficacy safety data , otherwise , contraindicate participation clinical trial new chemical entity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GLP-1 ,</keyword>
	<keyword>Type 2 Diabetes ,</keyword>
	<keyword>pharmacokinetics ,</keyword>
	<keyword>pharmacodynamics ,</keyword>
	<keyword>GSK716155 ,</keyword>
	<keyword>metformin ,</keyword>
	<keyword>exenatide</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>